Halt Medical is focused on establishing a new standard of care for women with symptomatic uterine fibroids. A shocking 35 million women suffer from fibroids, 7 million are symptomatic, 2 million seek treatment and roughly 0.3 million get treated. Our Company has developed and launched the patented Acessa™ Procedure, using widely accepted, radiofrequency (RF) ablation to destroy uterine fibroids. The procedure is cleared by the FDA and has CE mark for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The results of two U.S. and international trials, have proven safety, efficacy and durability. These data have generated 20 publications and three-year follow up.
Advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids through innovative and easy-to-use technologies.
Women have more options.